Memory Pharmaceuticals 8-K 2008
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Memory Pharmaceuticals Corp.
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Item 8.01 Other Events.
On May 2, 2008, Memory Pharmaceuticals Corp. (the "Registrant") announced that Roche has exercised its option to further develop and commercialize the Registrant’s lead nicotinic alpha-7 agonist drug candidate, MEM 3454, for neurological and psychiatric disorders. Roche’s exercise of its option for MEM 3454 triggers a $6 million milestone payment and entitles the Registrant to future payments upon the achievement of additional milestones and royalties on product sales, including a $17 million milestone payment upon the completion of the ongoing Phase 2a study of MEM 3454 in cognitive impairment associated with schizophrenia.
Item 9.01 Financial Statements and Exhibits.
Press Release dated May 2, 2008.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.